Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma

Tumori

Volumn 93, Issue 1, 2007, Pages 68-74

  Kwak, Cheol ^a   Yong, Hyun Park ^a   Chang, Wook Jeong ^a   Jeong, Hyeon ^a   Sang, Eun Lee ^a   Ja, Hyeon Ku ^b  

^a Seoul National University   (South Korea)

^b Seoul Veterans Hospital   (South Korea)

Author keywords

Immunotherapy; Metastasis; Prognosis; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; INTERLEUKIN 2;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE ESCALATION; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; NEPHRECTOMY; PROGNOSIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 33947725707     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160709300112     Document Type: Article

References (47)

1. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z: Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol, 12: 206-212, 1994.
2. Robson CJ, Churchill BM, Anderson W: The results of radical nephrectomy for renal cell carcinoma. J Urol, 101: 297-301, 1969.
3. Kuczyk MA, Anastasiadis AG, Zimmermann R, Merseburger AS, Corvin S, Stenzl A: Current aspects of the surgical management of organ-confined, metastatic, and recurrent renal cell cancer. BJU Int, 96: 721-727, 2005.
4. Pantuck A, Zisman A, Belldegrun A: RCC 2000: Changing the natural history of renal cell carcinoma. J Urol, 166: 1611-1623, 2001.
5. Bretheau D, Lechevallier E, de Fromont M, Sault MC, Rampal M, Coulange C: Prognostic value of nuclear grade of renal cell carcinoma. Cancer, 76: 2543-2549, 1995.
6. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res, 48: 7310-7313, 1988.
7. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol, 17: 2530-2540, 1999.
8. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P: A postoperative prognostic nomogram for renal cell carcinoma. J Urol, 166: 63-67, 2001.
9. Cindolo L, de la Taille A, Messina G, Romis L, Abbou CC, Altieri V, Rodriguez A, Patard JJ: A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int, 92: 901-905, 2003.
10. Palmer PA, Vinke J, Philip T, Negrier S, Atzpodien J, Kirchner H, Oskam R, Franks CR: Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol, 3: 475-480, 1992.
11. Fossa SD, Kramar A, Droz JP: Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer, 30A: 1310-1314, 1994.
12. Giberti C, Oneto F, Martorana G, Rovida S, Carmignani G: Radical nephrectomy for renal cell carcinoma: long-term results and prognostic factors on a series of 328 cases. Eur Urol, 31: 40-48, 1997.
13. van der Poel HG, Mulders PF, Oosterhof GO, Schaafsma HE, Hendriks JC, Schalken JA, Debruyne FM: Prognostic value of karyometric and clinical characteristics in renal cell carcinoma. Quantitative assessment of tumor heterogeneity. Cancer, 72: 2667-2674, 1993.
14. Lissoni P, Barni S, Ardizzoia A, Crispino S, Paolorossi F, Andres M, Scardino E, Tancini G: Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncology, 51: 59-62, 1994.
15. Mani S, Todd MB, Katz K, Poo WJ: Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol, 154: 35-40, 1995.
16. Miyao N, Oda T, Shigyou M, Takeda K, Masumori N, Takahashi A, Kitamura H, Tsukamoto T: Pre-operatively determined prognostic factors in metastatic renal cell carcinoma. Eur Urol, 31: 292-296, 1997.
17. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. Groupe Français d'Immunotherapie. N Engl J Med, 338: 1272-1278, 1998.
18. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS: Resection of metastatic renal cell carcinoma. J Clin Oncol, 16: 2261-2266, 1998.
19. van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM: Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol, 35: 197-203, 1999.
20. Lopez Hanninen E, Kirchner H, Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol, 155: 19-25, 1996.
21. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE: Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol, 11: 1368-1375, 1993.
22. Citterio G, Bertuzzi A, Tresoldi M, Galli L, Di Lucca G, Scaglietti U, Rugarli C: Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients. Eur Urol, 31: 286-291, 1997.
23. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol, 13: 688-696, 1995.
24. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P: Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 24: 3101-3106, 2006.
25. Spencer WF, Linehan WM, Walther MM, Haas GP, Lotze MT, Topalian SL, Yang JC, Merino MJ, Lange JR, Pockaj BA: Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J Urol, 147: 24-30, 1992.
26. Robertson CN, Linehan WM, Pass HI, Gomella LG, Haas GP, Berman A, Merino M, Rosenberg SA: Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol, 144: 614-617, 1990.
27. Sella A, Swanson DA, Ro JY, Putnam JB Jr, Amato RJ, Markowitz AB, Logothetis CJ: Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol, 149: 19-21, 1993.
28. Wagner JR, Walther MM, Linehan WM, White DE, Rosenberg SA, Yang JC: Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol, 162: 43-45, 1999.
29. Rackley R, Novick A, Klein E, Bukowski R, McLain D, Goldfarb D: The impact of adjuvant nephrectomy on multi-modality treatment of metastatic renal cell carcinoma. J Urol, 152: 1399-1403, 1994.
30. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet, 358: 966-970, 2001.
31. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med, 345: 1655-1659, 2001.
32. Itano NB, Blute ML, Spotts B, Zincke H: Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol, 164: 322-325, 2000.
33. Dreicer R, Galbraith SS, Davis CS, See WA: Surgical resection of metastatic renal cell carcinoma: The University of Iowa experience. Urol Oncol, 3: 99-101, 1997.
34. Kozlowski JM: Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites. Urol Clin North Am, 21: 601-624, 1994.
35. Kierney PC, van Heerden JA, Segura JW, Weaver AL: Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol, 1: 345-352, 1994.
36. Atkins MB, Regan M, McDermott D: Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res, 10 (Suppl): 6342S-6346S, 2004.
37. Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen PL: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol, 17: 2859-2867, 1999.
38. Medical Research Council Renal Cancer Collaborators: Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet, 353: 14-17, 1999.
39. Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Fenner M, Poliwoda H: Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer, 29A (Suppl 5): S6-S8, 1993.
40. Ellerhorst JA, Sella A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M, Logothetis CJ: Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer, 80: 2128-2132, 1997.
41. Elias L, Binder M, Mangalik A, Clark D, Morrison B, Altobelli KK, Smith A: Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-alpha for advanced renal cell carcinoma. Am J Clin Oncol, 22: 156-161, 1999.
42. Atzpodien J, Hoffmann R, Franzke M, Stief C, Wandert T, Reitz M: Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer, 95: 1045-1050, 2002.
43. Elias L, Lew D, Figlin RA, Thompson ME, Triozzi PL, Belt RJ, Wood DP Jr, Rivkin SE, David E: Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma. Cancer, 89: 597-603, 2000.
44. Dutcher JP, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, Sosman J, Lotze M, Gordon M, Logan T, Mier J: Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. Cancer J Sci Am, 3 (suppl 1): S73-S78, 1997.
45. Tourani JM, Pfister C, Berdah JF, Benhammouda A, Salze P, Monnier A, Paule B, Guillet P, Chretien Y, Brewer Y, Di Palma M, Untereiner M, Malaurie E, Tadrist Z, Pavlovirch JM, Hauteville D, Mejean A, Azagury M, Mayeur D, Lucas V, Kralowski I, Larregain-Fournier D, Abourachid H, Andrieu JM, Chastang C: Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol, 16: 2505-2513, 1998.
46. O'Brien MF, Rea D, Rogers E, Bredin H, Butler M, Grainger R, McDermott TE, Mullins G, O'Brien A, Twomey A, Thornhill J: Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience. Eur Urol, 45: 613-618, 2004.
47. Larkin JM, Gore ME: The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progress. Clin Oncol, 17: 319-321, 2005.